Skip to Main Content

Paper Details

Rational Combination of CRM1 Inhibitor Selinexor and Olaparib Shows Synergy in Ovarian Cancer Cell Lines and Mouse Models.
Mol Cancer Ther
7
2021
A2780luc ip1, CRM1, DNA, MTT, Mouse, OVCAR5, Olaparib, Ovarian Cancer, Ovarian Cancer Cell Lines, PARP, Selinexor, mouse, olaparib, ovarian and other cancers, ovarian cancer, selinexor, tumor, tumor nodules
Author NameAffiliation
Cristina IvanThe University of Texas MD Anderson Cancer Center
Prahlad T RamThe University of Texas MD Anderson Cancer Center
Anil K SoodThe University of Texas MD Anderson Cancer Center
  • 1 - 3

Datasets

Release 1.2